Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1966 1
1972 2
1974 2
1975 1
1976 2
1977 1
1978 1
1979 5
1980 1
1981 2
1982 5
1983 6
1984 5
1985 7
1986 6
1987 14
1988 19
1989 34
1990 14
1991 25
1992 20
1993 18
1994 14
1995 25
1996 20
1997 15
1998 20
1999 21
2000 35
2001 44
2002 41
2003 60
2004 85
2005 128
2006 139
2007 156
2008 163
2009 183
2010 211
2011 182
2012 172
2013 259
2014 268
2015 249
2016 270
2017 241
2018 193
2019 181
2020 216
2021 216
2022 215
2023 223
2024 55

Text availability

Article attribute

Article type

Publication date

Search Results

4,114 results

Results by year

Filters applied: . Clear all
Page 1
Diagnosis and Treatment of Pulmonary Arterial Hypertension: A Review.
Ruopp NF, Cockrill BA. Ruopp NF, et al. JAMA. 2022 Apr 12;327(14):1379-1391. doi: 10.1001/jama.2022.4402. JAMA. 2022. PMID: 35412560 Review.
IMPORTANCE: Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characterized by pulmonary arterial remodeling. ...Pulmonary arterial hypertension is 1 of the 5 groups of PH and i …
IMPORTANCE: Pulmonary arterial hypertension (PAH) is a subtype of pulmonary hypertension (PH), characteri …
Pulmonary Hypertension: A Contemporary Review.
Johnson S, Sommer N, Cox-Flaherty K, Weissmann N, Ventetuolo CE, Maron BA. Johnson S, et al. Am J Respir Crit Care Med. 2023 Sep 1;208(5):528-548. doi: 10.1164/rccm.202302-0327SO. Am J Respir Crit Care Med. 2023. PMID: 37450768 Review.
Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH) associated with lung disease, and chronic thromboembolic PH cast new light on the pathogenetic mechanisms, epidemiology, diagnostic approach, and therapeutic armament …
Major advances in pulmonary arterial hypertension, pulmonary hypertension (PH) associated with lung disea …
Pulmonary arterial hypertension.
Luna-López R, Ruiz Martín A, Escribano Subías P. Luna-López R, et al. Med Clin (Barc). 2022 Jun 24;158(12):622-629. doi: 10.1016/j.medcli.2022.01.003. Epub 2022 Mar 9. Med Clin (Barc). 2022. PMID: 35279313 Review. English, Spanish.
Pulmonary arterial hypertension (PAH) is a rare disease characterized by adverse remodeling of the arterial tree leading to increased vascular resistance with subsequent increase in right ventricular afterload and eventual development of heart failure.
Pulmonary arterial hypertension (PAH) is a rare disease characterized by adverse remodeling of the arterial tree
Pulmonary Arterial Hypertension.
Hassoun PM. Hassoun PM. N Engl J Med. 2021 Dec 16;385(25):2361-2376. doi: 10.1056/NEJMra2000348. N Engl J Med. 2021. PMID: 34910865 Review. No abstract available.
Treatment of pulmonary arterial hypertension: recent progress and a look to the future.
Humbert M, Sitbon O, Guignabert C, Savale L, Boucly A, Gallant-Dewavrin M, McLaughlin V, Hoeper MM, Weatherald J. Humbert M, et al. Lancet Respir Med. 2023 Sep;11(9):804-819. doi: 10.1016/S2213-2600(23)00264-3. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591298 Review.
Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary pulmonary hypertension caused by pulmonary vascular remodelling. ...In considering future directions for the field, our ambition is to identify therapie
Pulmonary arterial hypertension (PAH) is a severe but treatable form of pre-capillary pulmonary hypertension
The physiological basis of pulmonary arterial hypertension.
Naeije R, Richter MJ, Rubin LJ. Naeije R, et al. Eur Respir J. 2022 Jun 16;59(6):2102334. doi: 10.1183/13993003.02334-2021. Print 2022 Jun. Eur Respir J. 2022. PMID: 34737219 Free PMC article. Review.
Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a progressive increase in pulmonary vascular resistance and eventual right ventricular (RV) failure. ...Right heart failure is then diagnosed by imaging of increased ri
Pulmonary arterial hypertension (PAH) is a rare dyspnoea-fatigue syndrome caused by a progressive increase in pulmon
Paediatric pulmonary arterial hypertension: updates on definition, classification, diagnostics and management.
Rosenzweig EB, Abman SH, Adatia I, Beghetti M, Bonnet D, Haworth S, Ivy DD, Berger RMF. Rosenzweig EB, et al. Eur Respir J. 2019 Jan 24;53(1):1801916. doi: 10.1183/13993003.01916-2018. Print 2019 Jan. Eur Respir J. 2019. PMID: 30545978 Free PMC article. Review.
Paediatric pulmonary arterial hypertension (PAH) shares common features of adult disease, but is associated with several additional disorders and challenges that require unique approaches. This article discusses recent advances, ongoing challenges and distinc …
Paediatric pulmonary arterial hypertension (PAH) shares common features of adult disease, but is associated with severa …
State-of-the-art evidence in the treatment of systemic sclerosis.
Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. Pope JE, et al. Nat Rev Rheumatol. 2023 Apr;19(4):212-226. doi: 10.1038/s41584-023-00909-5. Epub 2023 Feb 27. Nat Rev Rheumatol. 2023. PMID: 36849541 Free PMC article. Review.
Patients with rapidly progressive early dcSSc might be eligible for autologous haematopoietic stem cell transplantation, which can improve survival. Morbidity from interstitial lung disease and pulmonary arterial hypertension is improving with the use of prov …
Patients with rapidly progressive early dcSSc might be eligible for autologous haematopoietic stem cell transplantation, which can improve s …
Pulmonary hypertension associated with lung disease: new insights into pathomechanisms, diagnosis, and management.
Olsson KM, Corte TJ, Kamp JC, Montani D, Nathan SD, Neubert L, Price LC, Kiely DG. Olsson KM, et al. Lancet Respir Med. 2023 Sep;11(9):820-835. doi: 10.1016/S2213-2600(23)00259-X. Epub 2023 Aug 14. Lancet Respir Med. 2023. PMID: 37591300 Review.
The pulmonary vasculopathy is distinct from that of other forms of pulmonary hypertension, with vascular ablation due to loss of small pulmonary vessels being a key feature. ...Most drugs approved for pulmonary arterial hypertension
The pulmonary vasculopathy is distinct from that of other forms of pulmonary hypertension, with vascular ablation due t …
Pulmonary hypertension in connective tissue diseases: epidemiology, pathogenesis, and treatment.
Cansu DÜ, Korkmaz C. Cansu DÜ, et al. Clin Rheumatol. 2023 Oct;42(10):2601-2610. doi: 10.1007/s10067-022-06446-y. Epub 2022 Nov 17. Clin Rheumatol. 2023. PMID: 36396789 Review.
Pulmonary hypertension (PH) is a clinical condition characterized by increased pulmonary arterial pressure arising from a heterogeneous range of diseases that has a deteriorating effect on the quality of life and may cause early mortality if left untre
Pulmonary hypertension (PH) is a clinical condition characterized by increased pulmonary arterial pressure arisi
4,114 results